Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements-Reference-Cited by-同舟云学术

Therapeutic drug monitoring of anti‐tumour necrosis factor‐α agents in inflammatory bowel disease: Limits and improvements

Published:2020-12-07 Issue:5 Volume:87 Page:2216-2227
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit Jnl Clinical Pharma

Author:

Giráldez‐Montero José María¹²³^ORCID,Gonzalez‐Lopez Jaime¹²^ORCID,Campos‐Toimil Manuel⁴³,Lamas‐Díaz María Jesús²

Affiliation:

1. Department of Pharmacy Hospital Clínico Universitario de Santiago de Compostela (SERGAS) Santiago de Compostela Spain

2. Clinical Pharmacology Group, Hospital Clínico Universitario de Santiago de Compostela (SERGAS) Health Research Institute of Santiago de Compostela (IDIS) Santiago de Compostela Spain

3. Department of Pharmacology, Pharmacy and Pharmaceutical Technology University of Santiago de Compostela Santiago de Compostela Spain

4. Group of Research on Physiology and Pharmacology of Chronic Diseases (FIFAEC), Center for Research in Molecular Medicine and Chronic Diseases (CIMUS) University of Santiago de Compostela (USC) Santiago de Compostela Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14654

Reference90 articles.

1. The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

2. Is Therapeutic Drug Monitoring for Anti-tumour Necrosis Factor Agents in Adults With Inflammatory Bowel Disease Ready for Standard of Care? A Systematic Review and Meta-analysis

3. A simple clinical colitis activity index

4. Comparing disease activity indices in ulcerative colitis

5. Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study;Pediatric Discovery;2024-06-25

2. Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA;Pharmaceutics;2023-11-11

3. Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review;FARM HOSP;2021